Evaluation of in vitro and in vivo genotoxicity of Angelica acutiloba in a standard battery of assays

• Main Authors: Jun-Won Yun, Yun-Soon Kim, Euna Kwon, Seung-Hyun Kim, Ji-Ran You, Hyeon Hoe Kim, Jeong-Hwan Che, Byeong-Cheol Kang
• Format: Article
• Language: English
• Published: BMC 2017-12-01
• Series: Laboratory Animal Research
• Subjects: Angelica acutiloba; traditional medicine; genotoxicity; mutagenicity
• Online Access: http://link.springer.com/article/10.5625/lar.2017.33.3.231

Abstract Among three representative species of Angelica found in Asian countries, including Korea, China, and Japan, Angelica acutiloba (AA) has been used as traditional herbal medicine with antitumor, antiinflammatory, anti-obesity, and anti-diabetes activities. In this study, the potential genotoxicity and mutagenicity of the AA extract were examined in a battery of in vitro and in vivo tests (bacterial reverse mutation assay, in vitro chromosomal aberrations assay, and in vivo micronucleus assay) in accordance with the test guidelines for toxicity testing developed by the Organization for Economic Cooperation and Development. Upon testing in the bacterial mutation assay (Ames test) using five Salmonella typhimurium TA98, TA100, TA102, TA1535 and TA1537, no significant increase the number of revertant colonies in the metabolic activation system and non-activation system was noted in the AA extract groups. Also, in the chromosome aberration test, the AA extract did not cause chromosomal aberration with or without metabolic activation by S9 mix. A bone marrow micronucleus test of mice demonstrated that the incidence of micronucleated polychromatic erythrocytes in the AA extract groups (500, 1000 and 2000 mg/kg BW) was equivalent to that of the negative control group. Based on these results from a standard battery of assays, the AA extract was concluded to have no genotoxic at the proper dose.